Developments in topical retinoid therapy for acne

Seminars in Cutaneous Medicine and Surgery

Volumn 20, Issue 3, 2001, Pages 154-161

  Bershad, S ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL) 1 PROPENYL]BENZOIC ACID ETHYL ESTER; ACETRETIN; ADAPALENE; ALTINAC; ANTIBIOTIC AGENT; CELL NUCLEUS RECEPTOR; CLINDAMYCIN; ERYTHROMYCIN; ISOTRETINOIN; RETIN A MICRO; RETINAL; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID; RETINOL; RETINOL DERIVATIVE; TAZAROTENE; UNCLASSIFIED DRUG;

ACNE; CREAM; DERMIS; DRUG ABSORPTION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; EPIDERMIS; GEL; HUMAN; REVIEW; SKIN IRRITATION; SLOW RELEASE FORMULATION;

EID: 0034804583     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1053/sder.2001.27555     Document Type: Review

References (77)

1. Tissue changes following deprivation of fat soluble vitamin A
2. Retinoid metabolism in the skin
3. What are natural retinoids?
4. Retinoids and the skin
5. 13-cis-retinoic acid is an endogenous compound in human serum
6. Regulation of the expression of epidermal keratinocyte proliferation and differentiation by vitamin A analogs
7. Retinoids and keratinocyteb differentiation in vitro
8. An ultrastructural study of the effects of topical tretinoin on microcomedones
9. Molecular mechanisms of tazarotene action in psoriasis
10. Isotretinoin in the treatment of acne
11. Zur kenntnis des vitamin-A aus fischtranen
12. Developments in the field of vitamins
13. Vitamin A: Its effect on acne: A study of one hundred patients
14. Zur lokalbehandlug von keratosen mit vitamin-A-saure
15. Prophylaxis of clinically induced benign and malignant epithelial tumors by retinoic acid
16. Topical vitamin A acid in acne vulgaris
17. Tretinoin (retinoic acid) in acne
18. Clinical experience with 0.025 percent retinoic acid solution ('Retin-A') in the topical treatment of acne
19. The induction of differentiation in teratocarcinoma cells by retinoic acid
20. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids)
21. Oral retinoids in dermatology
22. Retinoids, a new class of compounds with prophylactic and therapeutic activities in oncology and dermatology
23. Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid
24. The growing importance of topical retinoids in clinical dermatology: A retrospective and prospective analysis
25. Clinical pharmacology of 3 generations of retinoids
26. Current use and future potential role of retinoids in dermatology
27. A human retinoic acid receptor which belongs to the family of nuclear receptors
28. Nuclear receptor that identifies a novel retinoic acid response pathway
29. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling
30. Physiological and clinical aspects of vitamin A and its metabolites
31. The retinoid receptors
32. Terminal-group oxidation of retinol by mouse epidermis
33. The formation of all-trans-retinoic acid from all-trans-retinol in hairless mouse skin
34. Retinoic acid receptor gene expression in human skin
35. Endogenous retinoic acid receptor-retinoid X receptor heterodimers are the major functional forms regulating retinoid-responsive elements in adult human keratinocytes
36. Pharmacodynamics and pharmacokinetics of topical adapalene
37. Separation of the transactivation and AP1 antagonism functions of retinoic acid receptor
38. Retinoid antagonism of NF-IL6: Insight into the mechanism of antiproliferative effects of retinoids in Kaposi's sarcoma
39. Rational design of receptor-selective retinoids
40. Arotinoids: A new class of highly active retinoids
41. Efficacy and safety of CD 271 alcoholic gels in the topical treatment of acne vulgaris
42. The effect on rhino mouse skin of agents which influence keratinization and exfoliation
43. Follicular penetration
44. Tazarotene: First of a new generation of receptor-selective retinoids
45. Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations
46. Adapalene 0.1% gel is better tolerated than tretinoin 0.025% gel in acne patients
47. Tazarotene versus tretinoin or adapalene in the treatment of acne vulgaris
48. Retinoic acid receptor gamma mediates topical retinoid efficacy and irritation in animal models
49. The percutaneous absorption of topically applied tretinoin and its effect on endogenous concentrations of tretinoin and its metabolites after single doses or long-term use
50. Percutaneous absorption of AGN 190168, a new synthetic retinoid, through human skin in vivo
51. Skin distribution and pharmaceutical aspects of adapalene gel
52. Topical natural retinoids. The 'Proligand-non-ligand' concept
53. Molecular mechanisms of retinoid actions in skin
54. Comedolytic effect of topical retinaldehyde in the rhino mouse model
55. Clinical efficacy and safety of a topical combination of retinaldehyde 0.1% with erythromycin 4% in acne vulgaris
56. The clitical role of the vehicle to therapeutic efficacy and patient compliance
57. The Microsponge Delivery System (MDS): A topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives
58. Topical delivery system for tretinoin: Research and clinical implications
59. Comparative efficacy and safety of two 0.025% tretinoin gels: Results from a multicenter double-blind, parallel study
60. Reduced skin irritation with tretinoin containing polyolprepolymer-2, a new topical tretinoin delivery system: A summary of preclinical and clinical investigations
61. Comparison of adapalene 0.1% solution and tretinoin 0.025% gel in the treatment of acne vulgaris
62. Topical treatment of acne vulgaris: Retinoids and cutaneous irritation
63. The measurement of the stratum corneum reservoir. A predictive method for in vivo percutaneous absorption studies: Influence of application time
64. Tazarotene gel is safe and effective in the treatment of acne vulgaris: A multicenter, double-blind, vehicle-controlled study
65. Topical retinoids in the treatment of acne vulgaris
66. Successful treatment of acne vulgaris using a new method: Results of a randomized vehicle-controlled trial of short-contact therapy with tazarotene 0.1% gel
67. Efficacy and tolerability of combined topical treatment of acne vulgaris with tretinoin and erythromycin in general practice
68. A multicenter, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation (Velac®) applied once daily and a clindamycin lotion formulation (Dalacin T®) applied twice daily in the topical treatment of acne vulgaris
69. A placebo-controlled clinical trial to compare a gel containing a combination of isotretinoin (0.05%) and erythromycin (2%) with gels containing isotretinoin (0.05%) or erythromycin (2%) alone in the topical treatment of acne vulgaris
70. Propionibacterium acnes resistance to antibiotics in acne patients
71. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: A multicenter trial
72. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: A meta-analysis of five randomized trials
73. Pharmacokinetics and safety of tazarotene
74. Assay of comedolytic activity in acne patients
75. Future trends: A new generation of retinoids